Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon plus ribavirin vs DAAs in blood donors with chronic hepatitis C
ChiCTR-OPN-17011156Phase 4Not yet recruiting
- Sponsor
- Jurong People's Hospital
- Start
- May 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of interferon alfa and ribavirin in hepatitis C virus infection (2 arms), sponsored by Jurong People's Hospital. Primary endpoint: HCV-RNA. Planned start May 2017; status: not yet recruiting.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ChiCTR-OPN-17011156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17011156.